研究单位:[1]Chief of the Department of Interventional Neurology in Beijing Tiantan Hopital, Beijing Tiantan Hospital[2]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China,100000[3]Beijing Luhe Hospital Medical University,Beijing,Beijing,China,100000[4]Beijing Tiantan Hospital, Capital Medical University,Beijing,Beijing,China,100070[5]The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510000[6]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[7]Tangshan People's Hospital,Tangshan,Hebei,China,063000[8]Luoyang Central Hospital,Luoyang,Henan,China,471000[9]Henan Province People's Hospital,Zhengzhou,Henan,China,450000[10]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450000[11]Zhengzhou Central Hospital,Zhengzhou,Henan,China,450000[12]Taihe Hospital,Shiyan,Hubei,China,442000[13]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221000[14]Baotou Central Hospital,Baotou,Neimenggu,China,014000[15]Tangdu Hospital,Xi'an,Shaanxi,China,710000[16]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,China,710000[17]Qilu Hospital of Shandong University,Jinan,Shandong,China,250000[18]Liaocheng People's Hospital,Liaocheng,Shandong,China,252000[19]Qingdao Central Hospital,Qingdao,Shandong,China,266000[20]Weihai Central Hospital,Weihai,Shandong,China,264400[21]Yantaishan Hospital,Yantai,Shandong,China,264000[22]First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China,030000[23]Tianjin First Central Hospital,Tianjin,Tianjin,China,300000[24]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300000
This study is a prospective, multi-center, open-label, end-point blinded, randomized, parallel positive control, non-inferiority clinical trial, with a purpose to evaluate the safety and efficacy of Hemo Jirui intracranial thrombus aspiration catheter system for endovascular treatment of acute ischemic stroke by comparison with stent retriever (Solitaire FR). The trial is anticipated to last from November 2018 to May 2019, with 204 subjects recruited from 15-20 clinical trial centers in China.